Clinical Impact of Glucose Levels on Patient Outcome After Transcatheter Aortic Valve Replacement

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2025 Mar 3

PMID 40026524

Authors

Haitham Abu Khadija

Mohammad Alnees

Gera Gandelman

Mahdi Awwad

Tal Schiller

Yazan Hamdan

Omar Ayyad

Alena Kirzhner

Gal Sella

Yazid Kashquosh

Nadin Kakoush

Alex Blatt

Jacob George

Affiliations

Soon will be listed here.

Abstract

Background: Limited data are available for evaluating the effect of blood glucose on transcatheter aortic valve replacement (TAVR) outcomes in patients with diabetes. We aimed to assess the impact of glucose levels on short-term and long-term adverse outcomes in patients undergoing TAVR.

Methods And Results: Data from severe aortic stenosis (AS) patients who underwent TAVR from 2010 to 2022 were collected retrospectively. In total, 615 patients were enrolled in the study: Among the total patient population, 43% had diabetes mellitus (DM), with a mean hemoglobin A1c (HbA1c) level of 7.4 ± 2.5. Within this cohort, 33% were classified as having uncontrolled diabetes, while 17% were considered well-controlled. Diabetic patients were younger (80.7 ± 6.8 vs. 82.0 ± 6.8 years, = 0.001) and had more cardiovascular risk factors. No significant differences were found in outcomes between the two groups during the twelve-year follow-up. A multivariable logistic regression analysis was conducted on 270 DM patients to examine the impact of blood glucose levels and HbA1c on outcomes such as arrhythmia, stroke, and acute kidney injury (AKI). For arrhythmia, the odds ratio for HbA1c and blood glucose were 1.1039 ( = 0.23), and 0.998 ( = 0.76), indicating no significant associations. In stroke cases, HbA1c had an odds ratio of 1.194 ( = 0.36), while an odds ratio of 1.020 ( = 0.013) for blood glucose indicated a significant association. Notably, for AKI, the odds ratio for HbA1c was 2.304 ( = 0.02), indicating a significant link between higher HbA1c levels and increased AKI risk, with blood glucose levels trending toward significance (odds ratio = 1.0137, = 0.061).

Conclusions: Diabetic status is a predictor of short-term outcomes following TAVR. Thus, these screening parameters should be included in risk assessment tools for TAVR candidates.

References

Falcao-Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk C, van der Velden J . Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011; 124(10):1151-9. DOI: 10.1161/CIRCULATIONAHA.111.025270. View

Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson A, Miftaraj M . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 376(15):1407-1418. DOI: 10.1056/NEJMoa1608664. View

Beohar N, Doshi D, Thourani V, Jensen H, Kodali S, Zhang F . Association of Transcatheter Aortic Valve Replacement With 30-Day Renal Function and 1-Year Outcomes Among Patients Presenting With Compromised Baseline Renal Function: Experience From the PARTNER 1 Trial and Registry. JAMA Cardiol. 2017; 2(7):742-749. PMC: 5710618. DOI: 10.1001/jamacardio.2017.1220. View

Kitai T, Miyakoshi C, Morimoto T, Yaku H, Murai R, Kaji S . Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. JAMA Netw Open. 2020; 3(5):e204296. PMC: 7206504. DOI: 10.1001/jamanetworkopen.2020.4296. View

Tzamalis P, Herzberger V, Bergmann J, Wuerth A, Bramlage P, Schroefel H . The association of diabetes mellitus treated with oral antidiabetic drugs and insulin with mortality after transcatheter valve implantation: a 3-year follow-up of the TAVIK registry. Cardiovasc Diabetol. 2019; 18(1):63. PMC: 6540569. DOI: 10.1186/s12933-019-0873-6. View

Mahmood M, Daud F, Ismail A . Glycaemic control and associated factors among patients with diabetes at public health clinics in Johor, Malaysia. Public Health. 2016; 135:56-65. DOI: 10.1016/j.puhe.2015.07.043. View

Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash S . Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed Pharmacother. 2018; 107:306-328. DOI: 10.1016/j.biopha.2018.07.157. View

Okoh A, Kambiz K, Unnikrishnan D, Fugar S, Sossou C, Thawabi M . Effect of Transcatheter Aortic Valve Implantation on Renal Function in Patients With Previous Renal Dysfunction. Am J Cardiol. 2019; 124(1):85-89. DOI: 10.1016/j.amjcard.2019.04.008. View

Faroux L, Chen S, Muntane-Carol G, Regueiro A, Philippon F, Sondergaard L . Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis. Eur Heart J. 2020; 41(29):2771-2781. DOI: 10.1093/eurheartj/ehz924. View

10.

Weil E, Lemley K, Yee B, Lovato T, Richardson M, Myers B . Podocyte detachment in type 2 diabetic nephropathy. Am J Nephrol. 2011; 33 Suppl 1:21-4. PMC: 3121550. DOI: 10.1159/000327047. View

11.

Abramowitz Y, Vemulapalli S, Chakravarty T, Li Z, Kapadia S, Holmes D . Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circ Cardiovasc Interv. 2017; 10(11). DOI: 10.1161/CIRCINTERVENTIONS.117.005417. View

12.

Izkhakov E, Rozenbaum Z, Margolis G, Khoury S, Keren G, Shacham Y . Prolonged Hyperglycemia and Renal Failure after Primary Percutaneous Coronary Intervention. Cardiorenal Med. 2019; 9(2):92-99. DOI: 10.1159/000495704. View

13.

Falcao-Pires I, Leite-Moreira A . Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2011; 17(3):325-44. DOI: 10.1007/s10741-011-9257-z. View

14.

Zhou X, Ruan X, Hao L, Zhou Y, Gu J, Qiu H . Optimal hemoglobin A1C cutoff value for diabetes mellitus and pre-diabetes in Pudong New Area, Shanghai, China. Prim Care Diabetes. 2018; 12(3):238-244. DOI: 10.1016/j.pcd.2017.12.006. View

15.

. 6. Glycemic Targets: . Diabetes Care. 2018; 42(Suppl 1):S61-S70. DOI: 10.2337/dc19-S006. View

16.

Qaseem A, Wilt T, Kansagara D, Horwitch C, Barry M, Forciea M . Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018; 168(8):569-576. DOI: 10.7326/M17-0939. View

17.

Braghiroli J, Kapoor K, Thielhelm T, Ferreira T, Cohen M . Transcatheter aortic valve replacement in low risk patients: a review of PARTNER 3 and Evolut low risk trials. Cardiovasc Diagn Ther. 2020; 10(1):59-71. PMC: 7044101. DOI: 10.21037/cdt.2019.09.12. View

18.

Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P . 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36):2739-2791. DOI: 10.1093/eurheartj/ehx391. View

19.

Culler S, Cohen D, Brown P, Kugelmass A, Reynolds M, Ambrose K . Trends in Aortic Valve Replacement Procedures Between 2009 and 2015: Has Transcatheter Aortic Valve Replacement Made a Difference?. Ann Thorac Surg. 2018; 105(4):1137-1143. DOI: 10.1016/j.athoracsur.2017.10.057. View

20.

Khan S, Dargham S, Suwaidi J, Jneid H, Abi Khalil C . Trends and Outcomes of Aortic Valve Replacement in Patients With Diabetes in the US. Front Cardiovasc Med. 2022; 9:844068. PMC: 8971926. DOI: 10.3389/fcvm.2022.844068. View